All the results collectively indicated that antagonism of CXCR2 could impacted functional CD8+ T cell and DC infiltration into tumor sites in the CRC mouse model, which indicated that these treatments could change the TME in the CRC mouse model into a worse situation. The gene discussed is CD8A; the disease is neoplasm.